Leadership & Pay ·
Addex Therapeutics appoints Jean-Philippe Rocher as Head of Pharmaceutical Development
ADXNAddex Therapeutics Ltd.
Addex Therapeutics announced executive management changes on October 2, 2026. Jean-Philippe Rocher was appointed Head of Pharmaceutical Development and member of the Executive Management, returning to the company after previously establishing its chemistry capabilities and serving at Neurosterix. Mikhail Kalinichev stepped down as Head of Translational Science to focus on a similar role at Neurosterix. Addex Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel small molecule allosteric modulators for neurological disorders.